OMIDRIA Special Ep.3: Performance and Clinical Outcomes of OMIDRIA in Cataract Surgery

This episode of ‘Peer2Peer: The Podcast’, focuses on clinical performance and results from studies conducted with OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%.  in cataract surgery. The episode, featuring Dr. Denise Visco and Dr. Steven Silverstein, highlights the potential advantages of OMIDRIA in cataract surgery shown by rigorous clinical trials, including improved patient compliance and reduced reliance on pain medications, without increasing the risk of complications.

 

This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner or other  products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.

 

Rayner, the Rayner logo, OMIDRIA, and the OMIDRIA logo are proprietary marks of Rayner. © 2023 Rayner Group, all rights reserved. US-OM-2300032 07/23

 

IMPORTANT SAFETY INFORMATION 

OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.